CITÓMICA
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (28)
2023
-
Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
Haematologica, Vol. 108, Núm. 4, pp. 969-980
-
Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study
Blood Cancer Journal, Vol. 13, Núm. 1
-
Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil
Cancers, Vol. 15, Núm. 5
2022
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols
British Journal of Haematology, Vol. 196, Núm. 3, pp. 670-675
-
Systematic evaluation of plasma signaling cascades by functional proteomics approaches: SARS-CoV-2 infection as model
Proteomics - Clinical Applications, Vol. 16, Núm. 6
2021
-
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
Leukemia Research, Vol. 109
-
B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients
Cancers, Vol. 13, Núm. 7
-
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia
Blood, Vol. 137, Núm. 14, pp. 1879-1894
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
-
Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma
Cancers, Vol. 13, Núm. 6, pp. 1-18
-
Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials
Hematological Oncology, Vol. 39, Núm. 4, pp. 529-538
-
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
Cancers, Vol. 13, Núm. 19
2020
-
A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial
Cancer Medicine, Vol. 9, Núm. 7, pp. 2317-2329
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
-
Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia
Haematologica
2019
-
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials
European Journal of Haematology, Vol. 102, Núm. 1, pp. 79-86
-
Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
Genes Chromosomes and Cancer, Vol. 58, Núm. 11, pp. 815-819